Effects of genome architecture and epigenetic factors on susceptibility of promoter CpG islands to aberrant DNA methylation induction

Genomics

Volumn 98, Issue 3, 2011, Pages 182-188

  Takeshima, Hideyuki ^a   Yamashita, Satoshi ^a   Shimazu, Taichi ^b   Ushijima, Toshikazu ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

Author keywords

Cancer; DNA methylation; Epigenetics; LINE; SINE; Target gene specificity

Indexed keywords

DNA; RNA POLYMERASE II;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER TISSUE; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER;

CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; EPITHELIAL CELLS; FEMALE; GENOME, HUMAN; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; PROMOTER REGIONS, GENETIC; RNA POLYMERASE II; TRANSCRIPTION, GENETIC;

EID: 80052156601     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2011.06.003     Document Type: Article

References (33)

1. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16:6-21.
2. Ito T. Role of histone modification in chromatin dynamics. J. Biochem. 2007, 141:609-614.
3. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
4. Laird P.W., Jaenisch R. The role of DNA methylation in cancer genetic and epigenetics. Annu. Rev. Genet. 1996, 30:441-464.
5. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
6. Soejima H., Zhao W., Mukai T. Epigenetic silencing of the MGMT gene in cancer. Biochem. Cell Biol. 2005, 83:429-437.
7. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer 2005, 5:223-231.
8. Lin J.C., Jeong S., Liang G., Takai D., Fatemi M., Tsai Y.C., Egger G., Gal-Yam E.N., Jones P.A. Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 2007, 12:432-444.
9. Nakajima T., Yamashita S., Maekita T., Niwa T., Nakazawa K., Ushijima T. The presence of a methylation fingerprint of Helicobacter pylori infection in human gastric mucosae. Int. J. Cancer 2009, 124:905-910.
10. Oka D., Yamashita S., Tomioka T., Nakanishi Y., Kato H., Kaminishi M., Ushijima T. The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers. Cancer 2009, 115:3412-3426.
11. Takeshima H., Yamashita S., Shimazu T., Niwa T., Ushijima T. The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res. 2009, 19:1974-1982.
12. De Smet C., Loriot A., Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol. Cell. Biol. 2004, 24:4781-4790.
13. Furuta J., Nobeyama Y., Umebayashi Y., Otsuka F., Kikuchi K., Ushijima T. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res. 2006, 66:6080-6086.
14. Hagihara A., Miyamoto K., Furuta J., Hiraoka N., Wakazono K., Seki S., Fukushima S., Tsao M.S., Sugimura T., Ushijima T. Identification of 27 5′ CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene 2004, 23:8705-8710.
15. Song J.Z., Stirzaker C., Harrison J., Melki J.R., Clark S.J. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 2002, 21:1048-1061.
16. Kondo Y., Shen L., Cheng A.S., Ahmed S., Boumber Y., Charo C., Yamochi T., Urano T., Furukawa K., Kwabi-Addo B., Gold D.L., Sekido Y., Huang T.H., Issa J.P. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 2008, 40:741-750.
17. Ohm J.E., McGarvey K.M., Yu X., Cheng L., Schuebel K.E., Cope L., Mohammad H.P., Chen W., Daniel V.C., Yu W., Berman D.M., Jenuwein T., Pruitt K., Sharkis S.J., Watkins D.N., Herman J.G., Baylin S.B. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 2007, 39:237-242.
18. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E., Bergman Y., Simon I., Cedar H. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 2007, 39:232-236.
19. Hahn M.A., Hahn T., Lee D.H., Esworthy R.S., Kim B.W., Riggs A.D., Chu F.F., Pfeifer G.P. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res. 2008, 68:10280-10289.
20. McCabe M.T., Lee E.K., Vertino P.M. A multifactorial signature of DNA sequence and polycomb binding predicts aberrant CpG island methylation. Cancer Res. 2009, 69:282-291.
21. Takeshima H., Ushijima T. Methylation destiny: Moira takes account of histones and RNA polymerase II. Epigenetics 2010, 5:89-95.
22. Gebhard C., Benner C., Ehrich M., Schwarzfischer L., Schilling E., Klug M., Dietmaier W., Thiede C., Holler E., Andreesen R., Rehli M. General transcription factor binding at CpG islands in normal cells correlates with resistance to de novo DNA methylation in cancer cells. Cancer Res. 2010, 70:1398-1407.
23. Feltus F.A., Lee E.K., Costello J.F., Plass C., Vertino P.M. DNA motifs associated with aberrant CpG island methylation. Genomics 2006, 87:572-579.
24. M.R. Estecio, J. Gallegos, C. Vallot, R.J. Castoro, W. Chung, S. Maegawa, Y. Oki, Y. Kondo, J. Jelinek, L. Shen, H. Hartung, P.D. Aplan, B.A. Czerniak, S. Liang, J.P. Issa, Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Res. 20 (2010) 1369-1382.
25. Tomilin N.V. Regulation of mammalian gene expression by retroelements and non-coding tandem repeats. Bioessays 2008, 30:338-348.
26. Gordon S., Akopyan G., Garban H., Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 2006, 25:1125-1142.
27. Thomas M.J., Seto E. Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key?. Gene 1999, 236:197-208.
28. Lodygin D., Epanchintsev A., Menssen A., Diebold J., Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res. 2005, 65:4218-4227.
29. Sato N., Fukushima N., Maitra A., Matsubayashi H., Yeo C.J., Cameron J.L., Hruban R.H., Goggins M. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 2003, 63:3735-3742.
30. Yamashita S., Tsujino Y., Moriguchi K., Tatematsu M., Ushijima T. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2′-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci. 2006, 97:64-71.
31. Yamashita S., Hosoya K., Gyobu K., Takeshima H., Ushijima T. Development of a novel output value for quantitative assessment in methylated DNA immunoprecipitation-CpG island microarray analysis. DNA Res. 2009, 16:275-286.
32. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., Lempicki R.A. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003, 4:P3.
33. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.